文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

急性肾损伤中肾脏替代治疗标准与加速启动策略的贝叶斯再分析(STARRT-AKI试验)

A Bayesian reanalysis of the Standard versus Accelerated Initiation of Renal-Replacement Therapy in Acute Kidney Injury (STARRT-AKI) trial.
PubMed 文献 · Crit Care · 2022-08-25
一句话结论STARRT-AKI试验贝叶斯再分析显示,加速启动肾脏替代治疗策略有临床重要获益的概率极低,且可能减少无肾脏替代治疗存活天数,不支持采用加速启动策略。

该研究为STARRT-AKI试验的贝叶斯再分析,纳入15个国家168个中心随机分组的2927例危重急性肾损伤患者,比较加速与标准启动肾脏替代治疗策略。主要终点90天全因死亡率在乐观、中立和悲观先验下的绝对差异分别为-0.39%(95%可信区间-3.46%至3.00%)、0.13%(-3.30%至3.40%)和0.64%(-2.53%至3.88%),效应量达到共识定义的最小临床重要差异的概率极低。加速组无肾脏替代治疗天数较少(中位绝对差异-3.55天,95%可信区间-6.38至-0.48),无住院天数两组相似(加速组中位多0.48天,95%可信区间-1.87至2.72)。结论不支持采用加速启动肾脏替代治疗策略。

要点

  • 在2927例危重急性肾损伤患者中,加速与标准启动肾脏替代治疗策略的90天全因死亡率绝对差异在中立先验下为0.13%(95%可信区间-3.30%至3.40%),无重要差异。
  • 效应量等于或大于共识定义的最小临床重要差异的概率极低,无论采用乐观、中立还是悲观先验。
  • 加速策略组无肾脏替代治疗天数较少,中位绝对差异-3.55天(95%可信区间-6.38至-0.48),加速策略与更多无肾脏替代治疗天数相关的概率为0.008。
  • 无住院天数两组相似,加速组中位绝对差异多0.48天(95%可信区间-1.87至2.72),加速策略有更多无住院天数的概率为0.66。
  • 作者结论认为这些发现不支持采用加速启动肾脏替代治疗策略。

适用人群与场景

  • 危重急性肾损伤患者,来自STARRT-AKI试验随机分组的2927例患者,涉及15个国家168个中心。

研究设计与关键结果

  • 研究类型为STARRT-AKI试验的贝叶斯再分析,纳入全部2927例随机患者,在15个国家168个中心进行。
  • 主要终点90天全因死亡率采用分层贝叶斯逻辑回归评估,比较加速与标准启动肾脏替代治疗策略:中立先验下绝对差异0.13%(95%可信区间-3.30%至3.40%),乐观先验下-0.39%(95%可信区间-3.46%至3.00%),悲观先验下0.64%(95%可信区间-2.53%至3.88%)。
  • 效应量等于或大于共识定义的最小临床重要差异的概率极低。
  • 次要终点无肾脏替代治疗天数:加速策略组中位绝对差异-3.55天(95%可信区间-6.38至-0.48),加速策略与更多无肾脏替代治疗天数相关的概率为0.008。
  • 次要终点无住院天数:加速策略组中位绝对差异多0.48天(95%可信区间-1.87至2.72),加速策略有更多无住院天数的概率为0.66。

证据类型、等级与局限

  • 证据类型:随机对照试验的贝叶斯再分析(二次分析)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,这些发现不支持采用加速启动肾脏替代治疗策略。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Timing of initiation of kidney-replacement therapy (KRT) in critically ill patients remains controversial. The Standard versus Accelerated Initiation of Renal-Replacement Therapy in Acute Kidney Injury (STARRT-AKI) trial compared two strategies of KRT initiation (accelerated versus standard) in critically ill patients with acute kidney injury and found neutral results for 90-day all-cause mortality. Probabilistic exploration of the trial endpoints may enable greater understanding of the trial findings. We aimed to perform a reanalysis using a Bayesian framework.

METHODS: We performed a secondary analysis of all 2927 patients randomized in multi-national STARRT-AKI trial, performed at 168 centers in 15 countries. The primary endpoint, 90-day all-cause mortality, was evaluated using hierarchical Bayesian logistic regression. A spectrum of priors includes optimistic, neutral, and pessimistic priors, along with priors informed from earlier clinical trials. Secondary endpoints (KRT-free days and hospital-free days) were assessed using zero-one inflated beta regression.

RESULTS: The posterior probability of benefit comparing an accelerated versus a standard KRT initiation strategy for the primary endpoint suggested no important difference, regardless of the prior used (absolute difference of 0.13% [95% credible interval [CrI] - 3.30%; 3.40%], - 0.39% [95% CrI - 3.46%; 3.00%], and 0.64% [95% CrI - 2.53%; 3.88%] for neutral, optimistic, and pessimistic priors, respectively). There was a very low probability that the effect size was equal or larger than a consensus-defined minimal clinically important difference. Patients allocated to the accelerated strategy had a lower number of KRT-free days (median absolute difference of - 3.55 days [95% CrI - 6.38; - 0.48]), with a probability that the accelerated strategy was associated with more KRT-free days of 0.008. Hospital-free days were similar between strategies, with the accelerated strategy having a median absolute difference of 0.48 more hospital-free days (95% CrI - 1.87; 2.72) compared with the standard strategy and the probability that the accelerated strategy had more hospital-free days was 0.66.

CONCLUSIONS: In a Bayesian reanalysis of the STARRT-AKI trial, we found very low probability that an accelerated strategy has clinically important benefits compared with the standard strategy. Patients receiving the accelerated strategy probably have fewer days alive and KRT-free. These findings do not support the adoption of an accelerated strategy of KRT initiation.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Zampieri FG, da Costa BR, Vaara ST, et al. A Bayesian reanalysis of the Standard versus Accelerated Initiation of Renal-Replacement Therapy in Acute Kidney Injury (STARRT-AKI) trial. Crit Care. 2022. PMID: 36008827. doi:10.1186/s13054-022-04120-y

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。